PRVB Provention Bio, Inc. Stock Quote

PRVB [NASD]

Index	-	P/E	-	EPS (ttm)	-1.49	Insider Own	8.30%	Shs Outstand	56.34M	Perf Week	-5.80%
Market Cap	823.48M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	0.25%	Shs Float	48.16M	Perf Month	-20.09%
Income	-76.50M	PEG	-	EPS next Q	-0.51	Inst Own	38.60%	Short Float	7.05%	Perf Quarter	7.13%
Sales	-	P/S	-	EPS this Y	-34.50%	Inst Trans	0.09%	Short Ratio	4.44	Perf Half Y	27.21%
Book/sh	2.40	P/B	5.88	EPS next Y	-18.00%	ROA	-62.30%	Target Price	-	Perf Year	-11.92%
Cash/sh	2.52	P/C	5.60	EPS next 5Y	-	ROE	-67.70%	52W Range	4.72 - 20.05	Perf YTD	-16.65%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-29.58%	Beta	-
Dividend %	-	Quick Ratio	9.20	Sales past 5Y	-	Gross Margin	-	52W Low	199.15%	ATR	1.24
Employees	19	Current Ratio	9.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.76	Volatility	8.72% 7.37%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-130.40%	Profit Margin	-	Rel Volume	1.27	Prev Close	14.53
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	Payout	-	Avg Volume	764.00K	Price	14.12
Recom	1.70	SMA20	-15.35%	SMA50	-13.78%	SMA200	2.29%	Volume	973,132	Change	-2.82%

Jun-16-20

Reiterated

H.C. Wainwright

Buy

$20 → $26

Jun-04-20

Initiated

RBC Capital Mkts

Outperform

$25

Jun-04-20

Initiated

Oppenheimer

Outperform

$29

Jan-24-20

Initiated

Cantor Fitzgerald

Overweight

$25

Jun-26-19

Reiterated

H.C. Wainwright

Buy

$8 → $20

Jun-10-19

Initiated

Chardan Capital Markets

Buy

$20

Feb-22-19

Initiated

SVB Leerink

Outperform

Jan-13-21 07:03PM	Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock PR Newswire -14.37%
Jan-12-21 04:26PM	Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire +8.36%
09:20AM	Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock? Zacks
Jan-06-21 04:05PM	Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference PR Newswire
Jan-04-21 07:00AM	Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals PR Newswire +7.79%
Dec-21-20 07:30AM	Provention Bio Announces Addition to NASDAQ Biotechnology Index PR Newswire
07:01AM	Companies Like Provention Bio (NASDAQ:PRVB) Are In A Position To Invest In Growth Simply Wall St.
Dec-15-20 07:30AM	Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 PR Newswire
Dec-10-20 12:02PM	Is PRVB A Good Stock To Buy Now? Insider Monkey +5.63%
Dec-08-20 08:55AM	JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection PR Newswire
Dec-04-20 08:14AM	New Strong Sell Stocks for December 4th Zacks
Nov-25-20 08:31AM	New Strong Sell Stocks for November 25th Zacks
Nov-11-20 07:30AM	Provention Bio to Present at the Stifel Virtual Healthcare Conference PR Newswire +5.46%
Nov-10-20 12:42PM	Oppenheimer Sees These 3 Stocks Skyrocketing Over 100% TipRanks
Nov-06-20 07:30PM	Provention Bio, Inc (PRVB) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:00AM	Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire -5.25%
06:15AM	Provention Bio, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 07:30AM	Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals PR Newswire +8.35%
Oct-29-20 07:30AM	Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020 PR Newswire
Oct-20-20 12:52PM	Have Insiders Been Buying Provention Bio, Inc. (NASDAQ:PRVB) Shares? Simply Wall St. -5.99%
Oct-01-20 07:30AM	Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D) PR Newswire +7.33%
Sep-30-20 04:05PM	Provention Bio Files Clinical Module for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals PR Newswire
Sep-08-20 08:55AM	Is the Options Market Predicting a Spike in Provention Bio (PRVB) Stock? Zacks
07:30AM	Provention Bio to Present at Upcoming Virtual Investor Conferences PR Newswire
Aug-31-20 07:30AM	Provention Bio Announces Initiation of Phase 2b PROACTIVE Study of PRV-015 (anti-IL-15) in Non-responsive Celiac Disease PR Newswire
Aug-25-20 10:00AM	AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab PR Newswire
Aug-19-20 10:46AM	Is Provention Bio, Inc. (NASDAQ:PRVB) Popular Amongst Insiders? Simply Wall St. +6.61%
Aug-13-20 07:38AM	2 Revolutionary Biotech Stocks to Buy Right Now Motley Fool
Aug-11-20 07:00AM	John K. Jenkins, MD Joins Provention Bio Board of Directors PR Newswire
Aug-06-20 07:00AM	Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire +6.21%
Aug-03-20 04:05PM	Provention Bio Appoints Heidy Abreu King-Jones as Chief Legal Officer PR Newswire +8.08%
Jul-30-20 07:00AM	Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020 PR Newswire
Jul-02-20 09:15AM	Why This Under-the-Radar Biotech Stock Could Skyrocket Motley Fool
Jun-30-20 04:30PM	Provention Bio Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of the Stockholders PR Newswire
Jun-29-20 07:00AM	Provention Bio Announces Inclusion in the Russell 3000 Index and Russell 2000 Index PR Newswire
Jun-22-20 04:01PM	Provention Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire -5.91%
03:17PM	Hedge Funds Are Selling Provention Bio, Inc. (PRVB) Insider Monkey
Jun-19-20 10:26AM	Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +6.52%
Jun-17-20 10:16PM	Provention Bio Announces Pricing of $95.7 Million Public Offering of Common Stock PR Newswire -6.76%
Jun-16-20 04:01PM	Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire +5.46%
08:37AM	Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in Session Zacks
Jun-15-20 05:02PM	Why Provention Bio Jumped Today Motley Fool +8.57%
12:02PM	Provention Bio's Teplizumab Continued to Significantly Delay the Onset of Insulin-Dependent Type 1 Diabetes (T1D) in Presymptomatic Patients PR Newswire
May-28-20 07:00AM	Provention Bio to Present at the Jefferies Virtual Healthcare Conference PR Newswire
May-20-20 07:00AM	Provention Bio Announces Changes to its Board of Directors PR Newswire
May-18-20 07:00AM	Provention Bio and Vactech Announce Publication of Proof-of-Concept Data for a Preclinical Prototype of Coxsackievirus B Vaccine PR Newswire
May-08-20 07:30PM	Provention Bio, Inc (PRVB) Q1 2020 Earnings Call Transcript Motley Fool +14.56%
Apr-30-20 07:00AM	Provention Bio to Report First Quarter 2020 Financial Results and Host Conference Call on Thursday, May 7, 2020 PR Newswire
Apr-16-20 07:00AM	Provention Bio Initiates Rolling Submission of Biologic License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals PR Newswire
Apr-01-20 09:09AM	Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session Zacks -14.02%
Mar-21-20 08:54AM	Insider Buying: The Provention Bio, Inc. (NASDAQ:PRVB) Co-Founder & Chief Scientific Officer Just Bought US$59k Worth Of Shares Simply Wall St.
Mar-17-20 08:48AM	The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment Benzinga
Mar-16-20 04:05PM	Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes PR Newswire -15.87%
Mar-12-20 07:05AM	Provention Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update PR Newswire -20.53%
07:00AM	Provention Announces Positive Data from Phase 1b PREVAIL Study of PRV-3279 PR Newswire
Mar-05-20 07:00AM	Provention Bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, March 12, 2020 PR Newswire
Feb-19-20 07:00AM	Provention Bio to Present at Upcoming Conferences PR Newswire
Feb-05-20 12:41PM	Should You Take Comfort From Insider Transactions At Provention Bio, Inc. (NASDAQ:PRVB)? Simply Wall St.
Jan-23-20 06:30AM	Johnson & Johnson Sold a Hot Biotech Stock Barrons.com
Jan-08-20 07:00AM	Provention Bio Appoints Jason Hoitt as Chief Commercial Officer PR Newswire
Dec-30-19 02:44PM	Weekly CEO Buys Highlight GuruFocus.com
Dec-17-19 05:19PM	Hedge Funds Have Never Been This Bullish On Provention Bio, Inc. (PRVB) Insider Monkey
Dec-12-19 07:00AM	Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA PR Newswire
Dec-05-19 06:15AM	Boston investment firm led by former Bain Capital exec fuels diabetes research American City Business Journals +5.52%
Dec-04-19 12:00PM	Here's Why Momentum Investors Will Love Provention Bio, Inc. (PRVB) Zacks
Nov-21-19 07:32AM	Will Provention Bio Continue to Surge Higher? Zacks
Nov-05-19 04:05PM	Provention Bio Reports Third Quarter 2019 Financial Results PR Newswire
Oct-29-19 12:52PM	Will Provention Bio (NASDAQ:PRVB) Spend Its Cash Wisely? Simply Wall St.
07:00AM	Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019 PR Newswire
Oct-24-19 07:00AM	Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency PR Newswire
Oct-22-19 07:00AM	Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease PR Newswire
Sep-26-19 07:00AM	Sean Doherty Joins Provention Bio Board of Directors PR Newswire
Sep-25-19 07:00AM	Provention Bio to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-24-19 07:00AM	Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing PR Newswire
Sep-19-19 07:39AM	The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga -14.18%
Sep-18-19 08:26PM	Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock PR Newswire
04:14PM	Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire
Aug-27-19 03:30PM	Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares Simply Wall St.
Aug-20-19 07:00AM	Provention Bio Announces Key Addition to its Leadership Team PR Newswire
Aug-09-19 08:15AM	Provention Bio Inc (PRVB) President and CEO Ashleigh Palmer Bought $96,990 of Shares GuruFocus.com +7.61%
Aug-08-19 07:00AM	Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus PR Newswire
Aug-06-19 07:00AM	Provention Bio Reports Second Quarter 2019 Financial Results PR Newswire -10.27%
Aug-05-19 12:21PM	A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga -6.76%
07:00AM	Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals PR Newswire
Jul-12-19 07:15AM	5 Best Biotech Stocks of 2019 So Far Motley Fool +6.48%
Jul-01-19 07:30AM	ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes PR Newswire
Jun-14-19 12:31PM	Why Consistent Trading Doesn't Always Lead To Consistent Results Benzinga
Jun-13-19 07:49AM	Provention Bio Cancels Secondary Offering, Shares Rally Benzinga -5.40%
07:27AM	Provention Bio's stock surges after calling off public stock offering MarketWatch
07:00AM	Provention Bio Announces Termination of Public Offering of Common Stock PR Newswire
Jun-12-19 08:44AM	2 Small Biotechs With Sagging Shares but Promising Prospects TheStreet.com
Jun-11-19 09:43AM	Company News For Jun 11, 2019 Zacks -12.62%
07:34AM	The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering Benzinga
Jun-10-19 05:32PM	Provention Bio Announces Proposed Public Offering of Common Stock PR Newswire +217.01%
01:04PM	Provention Bio News: Why PRVB Stock Is Skyrocketing Today InvestorPlace
Jun-09-19 01:05PM	A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years PR Newswire
May-27-19 11:02AM	Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful? Simply Wall St.
May-09-19 07:56AM	The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut Benzinga -27.45%
May-08-19 04:30PM	Provention Bio Reports First Quarter 2019 Financial Results PR Newswire
04:25PM	Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis PR Newswire

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drechsler Andrew T	Chief Financial Officer	Sep 02	Buy	11.72	2,000	23,440	20,000	Sep 02 05:00 PM
Ramos Eleanor	Chief Medical Officer	Sep 02	Buy	12.06	299	3,606	64,799	Sep 02 07:43 PM
Leon Francisco	Chief Scientific Officer	Aug 21	Buy	13.35	2,000	26,708	2,567,450	Aug 21 04:05 PM
Ramos Eleanor	Chief Medical Officer	Aug 20	Buy	13.23	2,500	33,075	64,500	Aug 20 06:52 PM
Palmer Ashleigh	President and CEO	Aug 18	Buy	12.69	500	6,345	2,566,300	Aug 18 06:10 PM
Palmer Ashleigh	President and CEO	Aug 17	Buy	12.83	2,800	35,924	2,565,800	Aug 17 07:20 PM
Drechsler Andrew T	Chief Financial Officer	Aug 13	Buy	13.01	1,750	22,768	18,000	Aug 13 07:01 PM
Leon Francisco	Chief Scientific Officer	Jun 24	Buy	15.43	2,000	30,862	2,565,450	Jun 24 04:22 PM
Bluestone Jeffrey	Director	Apr 10	Option Exercise	2.36	32,246	76,101	39,571	Apr 14 05:00 PM
Leon Francisco	Chief Scientific Officer	Mar 19	Buy	5.92	10,000	59,200	2,563,450	Mar 20 06:15 AM
Hoitt Jason	Chief Commercial Officer	Mar 19	Buy	5.43	4,500	24,435	4,500	Mar 20 06:15 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience